Myriad

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient's lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. The company is based in Salt Lake City, Utah. They operate in using information from their technologies that are given to doctors and patients to develop new molecular diagnostic products that help identify a patients risk of developing a disease and the proper drug treatment and therapy need to help the patient and lower their risk of disease progression or recurrence.

The founders of Myriad Genetics are Mark Skolnick, Walter Gilbert, Peter Meldrum, and Kevin Kimberlin. Their mission statement is “We believe in improving the healthcare management of patients by providing physicians and patients with critical information across multiple medical specialties that addresses unmet medical needs.” They are a global leader and pioneer in the molecular diagnostics field. They are leaders in diagnostics in treating breast, ovarian, colon, uterine, prostate, and pancreatic cancer. Myriad Genetics trades on the Nasdaq and the SIC code is 2835 and the stock symbol or ticker is MYGN.

Peter D. Meldrum serves as President and CEO of Myriad Genetics. He has been a director of the company since the beginning in 1991 and has been President and CEO of the company since November 1991. He has earned his Doctor of Engineering degree from University of Utah in 2009, a Doctor of Science degree from Westminster College in 2004, and M.B.A degree from University of Utah in 1974. James S. Evans is the Chief Financial Officer of Myriad Genetics. He joined Myriad Genetics in 1995 and was the Corporate Controller from 1995 until July 2005 when he was named Vice President a position he held until being named the CFO in November 2007. He has received his Bachelor of...